Related Experiment Videos
Drug-induced infiltrative lung disease
P H Camus1, P Foucher, P H Bonniaud
1Service de Pneumologie et de Réanirnation Respiratoire, Centre Hospitalier Universitaire de Dijon, Université de Bourgogne, France.
The European Respiratory Journal. Supplement
|January 31, 2002
Summary
Drug-induced infiltrative lung disease (DI-ILD) presents diverse patterns and frequencies, making diagnosis challenging. Early identification and drug cessation are crucial for improving patient prognosis in these respiratory conditions.
Area of Science:
- Pulmonology
- Pharmacology
- Toxicology
Background:
- A growing number of pharmaceutical agents are identified as causes of infiltrative lung disease (ILD).
- Beyond medications, biomolecules and medicinal plants can also trigger severe or irreversible respiratory conditions.
- Estimating the precise incidence of drug-induced infiltrative lung disease (DI-ILD) is complicated by numerous factors.
Purpose of the Study:
- To highlight the diverse clinical presentations of DI-ILD.
- To emphasize the importance of considering drug etiology in patients with ILD.
- To underscore the need for improved diagnostic and predictive strategies for DI-ILD.
Main Methods:
- Systematic review of literature on drug-induced lung diseases.
- Analysis of host and drug-specific factors influencing DI-ILD risk and patterns.
- Description of a newly developed web-based database for respiratory adverse drug reactions.
Main Results:
- DI-ILD encompasses a spectrum from mild infiltrates to fatal adult respiratory distress syndrome.
- Prognosis is variable, dependent on the specific drug and DI-ILD type.
- Corticosteroid efficacy is proven for some drug-induced ILDs, but evidence is lacking for others.
Conclusions:
- A comprehensive evaluation for potential drug involvement is essential in all ILD cases.
- Discontinuation of the causative agent can positively impact patient outcomes.
- Further research is required for advancements in the prevention and prediction of DI-ILD.